about
Characterizing Affective Instability in Borderline Personality DisorderCircumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studiesCorrelates of recovery of social functioning in types I and II bipolar disorder patientsReliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patientsEffects of the D1 Dopamine Receptor Agonist Dihydrexidine (DAR-0100A) on Working Memory in Schizotypal Personality DisorderEvaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trialNegative symptoms and cognitive deficits: what is the nature of their relationship?Social Cognition Psychometric Evaluation: Results of the Initial Psychometric StudyVirtual Reality Functional Capacity Assessment In Schizophrenia: Preliminary Data Regarding Feasibility and Correlations with Cognitive and Functional Capacity Performance.From clinical research to clinical practice: a 4-year review of ziprasidone.Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia.Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorderThe course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stayPsychometric properties of performance-based measurements of functional capacity: test-retest reliability, practice effects, and potential sensitivity to change.Communication abnormalities predict functional outcomes in chronic schizophrenia: differential associations with social and adaptive functionsPsychometric properties of a short form of the Affective Lability Scale (ALS-18).Latest developments in the matrics process.Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: examining the convergence of performance-based measures and self-reports.Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.Prediction of real-world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder.Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone.Differential effects of emotional information on interference task performance across the life span.Cognition in schizophrenia: Past, present, and future.The course of vocational functioning in patients with schizophrenia: Re-examining social drift.Development and cross-validation of the UPSA short form for the performance-based functional assessment of patients with mild cognitive impairment and Alzheimer disease.Development of a virtual reality assessment of everyday living skills.A Longitudinal Examination of the Moderating Effects of Symptoms on the Relationship between Functional Competence and Real World Functional Performance in Schizophrenia.The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder.Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum.Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms.The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.International assessment of functional skills in people with schizophrenia.Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panelSocial competence versus negative symptoms as predictors of real world social functioning in schizophrenia.Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.Factors influencing self-assessment of cognition and functioning in schizophrenia: implications for treatment studies.White matter changes in schizophrenia: evidence for myelin-related dysfunction.Assessing everyday functioning in schizophrenia: not all informants seem equally informative
P50
Q22241872-62DB5BF8-00F4-467B-8DA7-60E101A0643EQ22251051-A50D68AD-9114-47AB-A198-56BDB5127A28Q24632341-AF98A521-087F-42A8-86C9-02377C18D817Q27311539-A0DE539C-CA82-44F4-9BBF-356802133F38Q28264001-78259459-A636-4F82-8873-E4397E3300FDQ29038503-B8E18DB9-DDE7-4482-8FA8-51BB383DD3C9Q30434663-DE587E80-5551-44F0-93FC-9D3FE1EBD680Q30491348-8E5F35D0-0E14-45D7-AD43-57371E9BDFABQ30711959-5E6B92DE-86C0-4254-BF95-258A5D770A95Q30840149-7F2B3E1B-2103-4EE6-94E9-DE9BB70DDB81Q33230419-2E846B80-6C86-4D4D-87E8-CC650A5994A7Q33717601-9941A9FC-B3F0-4FB8-8E42-3EDEC44BE089Q33758362-05ED91A4-6372-4692-B6F3-2479756EBC1CQ33823404-F1ACFE45-676F-4D29-8C6A-0C30E0DC2537Q33846946-BBE83A1C-8B6C-47F3-8D1B-79CC28517FF4Q33922770-B841F254-9948-4B81-BACD-5CC951501E91Q33946087-E8C88754-005A-40A2-9198-B01B20D24465Q33969154-4B10D778-7999-4013-8A0A-1992B451E8BBQ34022739-21CCA1CA-8A5F-4A68-A23D-9EB6CF1EED3EQ34096784-95D3EC45-F639-45BE-97D4-0B7DA7CC0029Q34115962-51364CB5-7388-49DA-BBC3-A7B895A9EF58Q34161403-DBF0E5FA-6E2E-4B5B-A7E3-92D61583DC6DQ34202123-20272802-6125-46A2-8888-0BF93994C64CQ34224025-70BA382A-12E8-410A-AB17-B2DFD453B556Q34224064-4F192D11-91B8-4917-8AA0-CEE54F7EEB82Q34227134-9ECB684F-B3CD-4375-94D5-5B06F1062D1EQ34242847-CDB84F9C-6C5F-4CEE-9492-5999C12229C6Q34245341-483104DA-CE33-436A-8FBA-4531623BDB32Q34252311-A0E2BD4F-2CF8-4DEA-900E-834ADF9D6891Q34252367-C8B90558-6682-437F-9817-031FE2C68BD4Q34499221-49E9D5D1-794D-4884-8656-692F9388451FQ34499226-AD103288-F386-4A25-89FE-C4CC22A00787Q34564057-BA61EBD7-1FAD-4FD1-87AE-D99ECABDBB36Q34604227-6E76E51A-0E32-47B4-985A-3B50707B6EC7Q34644126-0E4D74E3-7362-40CF-8436-6A55CB6BAA0EQ34798909-BAF64121-5AB0-4300-96EE-79CC0F6B8B6FQ34985997-5F453BB0-C9D0-4972-B2D4-31603CDE9945Q35009716-F326740C-A791-422B-9C65-FC0C87579800Q35125866-9B7F035E-D7B0-4998-B73F-95E50A0DB6CBQ35175794-4207C491-3A2B-4281-8D5E-3EFDEDE8F44C
P50
description
American psychiatrist
@en
Amerikaans psychiater
@nl
psichiatra statunitense
@it
psikiatra estatubatuarra
@eu
psiquiatra estadounidense
@es
psiquiatra estadounidense
@gl
psiquiatra estauxunidense
@ast
psiquiatra norte-americano
@pt
psiquiatre estatunidenc
@ca
psychiatre américain
@fr
name
Philip D. Harvey
@ast
Philip D. Harvey
@en
Philip D. Harvey
@es
Philip D. Harvey
@nl
Philip D. Harvey
@sl
フィリップ・D・ハーヴィー
@ja
type
label
Philip D. Harvey
@ast
Philip D. Harvey
@en
Philip D. Harvey
@es
Philip D. Harvey
@nl
Philip D. Harvey
@sl
フィリップ・D・ハーヴィー
@ja
prefLabel
Philip D. Harvey
@ast
Philip D. Harvey
@en
Philip D. Harvey
@es
Philip D. Harvey
@nl
Philip D. Harvey
@sl
フィリップ・D・ハーヴィー
@ja
P106
P1153
7401432064
P1960
9MkfHTEAAAAJ
P2038
Philip_Harvey2
P21
P2798
P31
P496
0000-0002-9501-9366